

Lantern Pharma's [LP-184](#): Utilizing their AI platform, RADR®, Lantern Pharma has developed LP-184, a drug candidate that has received Fast Track Designation from the FDA for glioblastoma treatment. LP-184 is currently in Phase 1A clinical trials, showing promise in penetrating the blood-brain barrier and targeting tumor cells effectively.

From:

<https://neurosurgerywiki.com/wiki/> - **Neurosurgery Wiki**

Permanent link:

<https://neurosurgerywiki.com/wiki/doku.php?id=lp-184>

Last update: **2025/02/26 22:50**

